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CARs in the lead against Multiple Myeloma
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Abstract
The recent clinical success of CD19 directed chimeric antigen receptor (CAR) T-cell therapy in 
chronic and acute leukemia has led to increased interest in broadening this technology to other 
hematological malignancies and solid tumors. Now, advances are being made using CAR T cell 
technology to target myeloma antigens such as BCMA, CD138 and kappa-light chain as well as 
CD19 on putative myeloma stem cells. To date, only a limited multiple myeloma patients have 
received CAR-T cell therapy but preliminary results have been encouraging. In this review, we 
summarize the recently reported results of clinical trials conducted utilizing CAR T-cell therapy in 
MM.
Keywords
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Introduction
Multiple Myeloma (MM) is a hematological malignancy defined by the accumulation of 
clonal plasma cells within the bone marrow with evidence of end organ damage that can be 
attributed to the underlying plasma cell proliferative disorder. Evidence of disease includes 
lytic bone lesions and/or pathologic fractures, hypercalcemia, anemia, renal impairment and 
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increased susceptibility to opportunistic infections (1). As of 2016, the incidence of MM has 
reached 5.6 per 100,000 persons and accounts for approximately 10% of all hematological 
malignancies in the western world (1, 2). Traditionally, treatment of MM has focused on 
prolonging patient survival by reduction of malignant plasma cell burden followed by 
maintenance therapy. Recent insights into the pathophysiology of MM have led to the 
development of novel therapeutic agents, such as immune-modulatory drugs (e.g. 
lenalidomide, thalidomide, and pomalidomide) and proteasome inhibitors (e.g. bortezomib 
and carfilzomib). Over the last decade these new agents have revolutionized disease 
management and dramatically improved survival in newly diagnosed patients (3–5). When 
induction therapy utilizing these new agents is followed by autologous stem cell transplant 
(ASCT) and subsequent maintenance therapy, up to one-third of patients can achieve a 
complete response (CR) (3). Despite these recent treatment advances, disease recurrence still 
remains a major obstacle, with nearly all patients eventually relapsing with increasingly 
refractory disease (6). As MM remains an incurable disease, new treatment options are 
critical for these patients.
Chimeric Antigen Receptor T cells
The recent success of autologous CAR T-cells transduced to express a chimeric antigen 
receptor (CAR) targeting CD19 in relapsed/refractory (r/r) chronic lymphocytic leukemia 
CLL (CLL) (7, 8) and acute lymphoblastic leukemia (ALL) (9–11) has spurred new interest 
in broadening this technology to other hematological malignancies and solid tumors. CAR 
T-cells are genetically modified to express an antigen receptor recognizing a tumor 
associated surface antigen. Ideally, these tumor associated antigens would be uniquely 
expressed by the malignant cells and absent on normal tissues. In this way, CAR T-cells and 
their effector functions are redirected towards specific malignant targets in an MHC 
independent fashion.
Traditionally, CARs consist of an extracellular targeting region linked to various 
intracellular signaling domains. Targeting is achieved via a single-chain variable fragment 
(scFv) derived from a monoclonal antibody. The scFv is connected to the intracellular 
domains by a hinge/transmembrane region, commonly derived from CD8 or IgG4. The 
intracellular domains have conventionally consisted of either one (2nd generation CAR) or 
two (3rd generation CAR) co-stimulatory domains e.g. 4-1BB, CD28 or OX-40 linked to the 
cytoplasmic signaling domain of CD3ζ. The CD3ζ domain alone is not sufficient to drive 
optimal T-cell proliferation and cytokine production (12, 13), however the incorporation of 
various co-stimulatory domains can result in increased CAR T cell signaling, persistence 
and efficacy (14, 15). The effect of various co-stimulatory domains on T cell function differs 
in accordance with their original function. 4-1BBζ containing CARs have shown increased 
persistence and reduced exhaustion in vivo compared to CD28ζ CARs (14, 15), whereas 
CD28ζ CARs display increased cytokine production and may result in different kinetics of 
expansion following antigen stimulation. Although CD28ζ CARs appear to have faster and 
more robust functionality initially, they lack the ongoing persistence compared to their 
41BBζ counterparts (14). So far, the use of 3rd generation CARs equipped with multiple co-
stimulatory domains, have not shown increased efficacy compared to second generation 
CARs (14, 16).
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Limiting CAR T cell related toxicities
CAR related toxicities can be divided into on-target, off-tumor effects and systemic 
toxicities. One of the major challenges in developing new CAR constructs is the 
identification of suitable and unique targets. Ideally, the target antigen should be tumor 
specific and play a fundamental role in maintaining tumorogenicity in order to limit antigen 
escape, while also lacking expression on normal life-sustaining tissues. Beyond target-
mediated toxicities, CAR T-cells can also induce a systemic inflammatory syndrome termed 
cytokine release syndrome (CRS).
The issue of on-target, off-tumor effects, naturally varies based on the chosen antigen. Given 
the power of CAR-T cell therapy, targeting an antigen that is also expressed, even in low 
levels on normal tissues can have fatal consequences (17). The incorporation of a “suicide 
gene” into CAR T constructs allows for the elimination of CAR modified T cells in the event 
of toxicity (18, 19). Whether or not this approach will be beneficial depends on the depth 
and rapidity of CAR T-cell elimination, as CAR T-cell loss may take several days depending 
on the system used. Additional strategies include engineering CAR T cells to express 
specific chemokine receptors allowing direct homing to the tumor environment or 
minimizing trafficking to non-tumor sites (20, 21). Co-inhibitory receptors (iCAR) are also 
being investigated in an attempt to spare healthy tissue in the event of CAR recognition (22). 
This strategy is attractive, but requires identification of surface antigens that are only 
expressed on healthy tissue and not on tumor cells.
CRS is an increasingly recognized toxicity noted in various CAR T –cell trials in 
hematologic malignancies. In most patients, CRS symptoms are mild and include flu-like 
symptoms such as fever and mild hypotension. In more severe cases clinical features 
include: hypotension, hypoxia, capillary leak and coagulopathy all of which can potentially 
lead to fatal multi-organ dysfunction (23, 24). The hallmark of CRS is immune activation as 
noted by dramatic elevations in pro-inflammatory cytokines, such as IL-6, IL-10, IFN-γ and 
granulocyte macrophage-colony stimulating factor (GM-CSF) (17, 23, 24). In general, the 
presence of CRS correlates with expansion and activation of CAR T cells; in ALL, but not 
lymphomas, the severity of CRS is associated with increasing disease burden. The incidence 
and severity of CRS in patients receiving CAR T cells for multiple myeloma has not yet 
been defined. Although the clinical outcome of CAR therapy cannot be predicted on the 
basis of CRS severity, the majority of patients who respond to therapy do experience some 
degree of CRS. One challenge following recognition of CRS has been choosing an 
appropriate therapy that dampens the uncontrolled inflammatory response without reducing 
CAR T cell efficacy. Traditionally, management of CRS consisted of systemic 
administration of glucocorticoids, though prolonged glucocorticoid administration (e.g. > 14 
days) may also dampen or ablate the function of infused CAR T cells (9, 23). Given the 
recognition of IL-6 as a primary mediator of CRS, newer approaches to management have 
targeted IL-6 itself with anti IL-6 receptor (IL-6R) antibodies such as tocilizumab (11, 23). 
The effect of IL-6R blockade in relation to CAR T cell proliferation, persistence and anti-
tumor efficacy is still under investigation, but early data suggests that the use of anti-
cytokine agents does not limit the anti-tumor efficacy of CAR T cells.
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CARs in clinical trials for multiple myeloma
The interest in developing CARs that target MM has dramatically increased over the last few 
years. To date, the results of four clinical trials have been published and additional 
constructs are in development. The structure of these various CAR products differs with 
respect to targeted antigen, incorporation of co-stimulatory domains and reported anti-tumor 
efficacy in clinical trials (Figure 1).
CD19
CAR T-cells directed against CD19 have shown tremendous potential in hematological 
malignancies such as ALL and CLL (9, 11). CD19 expression is not traditionally associated 
with MM and is generally not considered a therapeutic target in this disease (25). Despite the 
lack of CD19 expression on the plasma cell clones, some studies have identified expression 
on a minor MM stem cell subset (26) making CD19 a potential target for eliminating 
recurrence following elimination of differentiated plasma cells. These MM stem cells have 
been associated with increased drug-resistance and are potentially responsible for the 
incurable nature of MM. This observation was the rationale for conducting a clinical trial 
using a CAR against CD19(27). Garfall and Maus et al. described one patient treated with an 
anti-CD19-4-1BB-CD3ζ CAR T-cell product (CTL019) (27). The patient underwent 
CTL019 infusion following high dose melphalan and autologous stem cell transplant. 
Following infusion of CAR T cells, no fever or other signs of CRS were noted however 
CTL019 cells were detected in both blood and bone marrow for up to 47 days following 
infusion. The patient was started on lenalidomide maintenance treatment 3 months later, as 
per standard of care. Disease evaluation after 12 months demonstrated maintenance of a 
complete response (CR) to CTL019. This durable response was achieved despite the absence 
of CD19 expression on 99.95% of the patient’s malignant cells.
At the annual meeting of the American Society of Hematology (ASH) in December 2016, 
investigators from U. Penn presented updated data from a safety and feasibility trial of MM 
patients treated with CTL019. In total, 12 patients were enrolled in the study with 10 
patients receiving infusion of CTL019 (5×107 CAR expressing T cells) 12–14 days after 
high-dose melphalan and ASCT. The treatment resulted in a median progression-free 
survival after ASCT + CTL019 of 185 days, with patients experiencing very good partial 
response (VGPR) n=6, partial response (PR) n=2 and progressive disease (PD) n=2. Overall, 
only minor adverse effects including mild CRS were observed and the product was well 
tolerated.
Although CD19 is expressed rarely on MM plasma cells, the presence of CD19 on a cancer 
stem-cell like population makes CD19 a potential target in combination with traditional 
therapies. Further studies are required to fully understand the mechanisms underlying the 
results reported in the CTL019 trials.
CD138
CD138, also known as syndecan 1, is a surface protein expressed on most healthy and 
malignant plasma cells (28). CD138 functions as an adhesion protein, binding collagen and 
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fibronectin molecules located in the extracellular matrix. Because CD138 is highly 
expressed on MM cells, it is considered an attractive target. In 2016 a group at the Chinese 
PLA General Hospital reported on the treatment of chemotherapy-refractory MM with a 
CD138 (CART138) directed, 4-1BBζ CAR construct (29). Five patients received 3–6 
CART138 injections following various combinations of pre-conditioning/induction therapy. 
Four out of five patients experienced mild fever, attributed to the second injection of CAR T 
cells. Four of five patients achieved stable disease (SD) ranging from three to seven months; 
CAR T cells were detected in bone marrow for upwards of 3 months. The fifth patient 
experienced PD and was transitioned to palliative care, despite detectable CART138 cells in 
bone marrow for 90 days. Data from this study are limited and should be interpreted 
cautiously. Despite the attractiveness of CD138 as a target for MM it does have potential 
drawbacks. First, CD138 is known to be expressed on epithelial tissues, and prior clinical 
trials investigating an anti-CD138-antibody drug-conjugate in MM treatment was notable for 
skin and/or mucosal toxicity (e.g. mucositis, stomatitis, hand/foot syndrome). Second, 
CD138 is shed from malignant cells thereby acting as a potential decoy for CD138 targeted 
T cells. Future studies targeting CD138 with CAR T cells may need to include strategies to 
avoid on-target toxicity while maintaining potential anti-tumor effects (30).
Kappa light chain
Given that mature B lymphocytes express either κ or λ light chains, but not both, Ramos et 
al. (31) recently developed a kappa-specific CAR construct that could recognize kappa 
restricted cells, while leaving the lambda-restricted subset intact, thereby maintaining at 
least partial humoral immunity. Although plasma cells do not express surface 
immunoglobulins (Igs), they reasoned that targeting the kappa-light chain may also be 
applicable to MM as several groups have described an MM-initiating population that 
expresses surface Igs (31). In their phase I clinical trial, seven MM patients were treated 
with a 2nd generation CD28-CD3ζ CAR T cell construct against the κ light chain 
(κ.CARTs). Patients received 1 – 2 infusions of κ.CARTs with a 50% reduction in the 
number of circulating B cells within the first two weeks of treatment. Encouragingly, the 
elimination of B cells was primarily of κ light chain origin. Four of seven MM patients 
experienced responses to infused κ.CARTs, with stable disease (>24 months), minimal 
residual disease, or overall improvement of disease symptoms. More robust responses were 
seen in the CLL and NHL patients likely due to their higher surface expression of κ light 
chain. The CAR T cell product was well tolerated and none of the patients experienced 
severe CRS.
BCMA
Recently, there has been much focus on the B-cell maturation antigen (BCMA) as a CAR 
target in MM. To date, four clinical trials are registered in the US using various CAR T-cell 
products against BCMA. BCMA is a cell surface protein exclusively expressed on the B-cell 
linage and is involved in the differentiation and maturation of B cells into plasma cells. 
BCMA is highly expressed on malignant MM plasma cells and provides a substantial anti-
apoptotic signal making it an encouraging target for BCMA-directed immunotherapy. The 
first results from a clinical trial, utilizing a 2nd generation anti-BCMA-CAR with CD28, was 
published by Ali et al., in 2016. The trial was designed as a phase I dose-escalation trial, 
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with 12 patients receiving either 0.3, 1, 3 or 9 × 106 CAR-positive T-cells per kg. Prior to 
CAR T-cell infusion, patients received lymphodepletion therapy (3 × 300 mg/m2 
cyclophosphamide and 3 × 30 mg/m2 fludarabine). The higher dose cohorts experienced 
more pronounced adverse effects attributed to CAR-T cells, including CRS. CAR-BCMA-
positive cells were detected in the blood of all patients in a dose dependent manner. 
Responses included a stringent CR (n=1), VGPR (n=2), PR (n=1) and SD for up to 16 weeks 
(n=8). The best responses occurred in the highest dose cohorts. Despite the concern for 
possible antigenic loss of BCMA following CAR T-cell therapy, only one patient in the 
CAR-BCMA study was reported to relapse with BCMA-negative MM clones in the bone 
marrow (32).
Two other BCMA-CAR products are currently being tested in clinical trials. Data from these 
trials were presented at the recent ASH meeting in 2016. Cohen et al., from the University of 
Pennsylvania, presented data from an ongoing phase I dose-escalation study, with a 2nd 
generation 4-1BB-CD3ζ anti-BCMA CAR. To date, six patients received CART-BCMA 
cells as split dose infusions (10% at day 0, 30% at day 1, and 60% at day 2). Five patients 
experienced CRS toxicity, with two patients requiring tocilizumab treatment. Interestingly, 
the two patients receiving tocilizumab had only received 40% of the planned CAR T cell 
dose due to fever. These patients experienced a robust anti-tumor response as demonstrated 
by a stringent CR and VGPR despite administration of tocilizumab and incomplete infusion 
of the targeted CAR T-cell dose. CART-BCMA cells were detected in both blood and bone 
marrow by PCR, with persistence reported for up to 7 months for the patient experiencing 
CR. Five months after therapy, the patient achieving a VGPR progressed, associated with a 
reduction in circulating CART-BCMA cells. Further analysis identified loss of BCMA 
expression on malignant cells, indicative of antigen escape. The remaining four patients 
experienced SD (n=1), minimal response (n=2) or PD (n=1), with minimal expansion of 
CART cells correlating to poorer responses (33). This same group also recently published a 
case report of posterior reversible encephalopathy syndrome (PRES) after infusion of anti-
BCMA CAR T-cells. They reported on a 55-year-old female with high-risk IgA lambda MM 
who developed worsening neurological toxicity requiring intubation following CAR-T cell 
infusion despite treatment with tocilizumab and high dose steroids; treatment with 
cyclophosphamide reversed the syndrome. The rapid reversibility and MRI appearance was 
felt to be most consistent with PRES. They postulated that high CSF levels of CRS-related 
cytokines may have caused the syndrome. Additionally, they demonstrated that 
cyclophosphamide may effectively reverse life-threatening, steroid-refractory CAR T cell 
neurotoxicity while retaining some CAR T cell efficacy and long-term persistence (34).
Blubird Bio reported data in December 2016, from a cohort of 9 patients with relapsed/
refractory MM who received infusion of an anti-BCMA CAR product (bb2121). Bb2121 is a 
2nd generation CAR T cell product with 4-1BB co-stimulation. Patients received a single 
infusion of bb2121 at various doses (5, 15 or 45 × 107 CAR T cells) after 
cyclophosphamide/fludarabine pre-conditioning. In all patients, CAR T cell expansion and 
persistence were observed, ranging from 4 to 24 weeks after infusion. The best response was 
achieved in the cohort treated with 15 × 107 CAR T cells, with two patients showing 
stringent CR and one patient VGPR. In the low-dose cohort, three patients initially achieved 
PR, SD and PD respectively. All patients in this cohort experienced disease progression 
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between eight and 11 weeks post CAR infusion. Overall, BCMA as antigen target for CART 
based immunotherapy seems promising with various clinical outcomes reflecting the various 
CAR construct design, dose, and baseline disease burden. Further studies are warranted, to 
determine the best BCMA CAR design for treatment of MM (35).
Conclusion
In this review, we have outlined the recent clinical data with CAR T cells as they transition 
as a platform from targeting B cell malignancies to targeting multiple myeloma with a 
variety of antigen targets. Multiple questions remain, including a thorough understanding of 
the potential toxicities specific to multiple myeloma, including cytokine release syndrome, 
the depth and duration of anti-tumor effects, and the role that CAR T cells may play in the 
management of MM, where there are multiple therapies available. So far, CARs utilizing 
BCMA seem to offer the most promise. As the field moves forward, new strategies to 
overcome the described limitations are being developed. With the introduction of dual-
targeting CARs (e.g. iCAR or CARs recognizing two antigens), future treatment of MM 
with CAR T cell therapy may result in longer-lasting efficacy and avoid antigen escape. As 
in other hematologic diseases, antigen escape is emerging as a new hurdle, and is likely due 
to the selective pressure exerted by CARs. Therefore, more research and development into 
the optimal CAR construct, with limited toxicities, no antigen escape and high anti-tumor 
efficacy is still needed. However, with combined efforts between academic institutions and 
their industry partners, CARs have the potential for offering definitive therapy for MM.
Abbreviations
MM Multiple Myeloma
ASCT autologous stem cell transplant
CAR Chimeric Antigen Receptor
r/r relapsed/refractory
CLL Chronic Lymphocytic Leukemia
ALL Acute Lymphoblastic Leukemia
scFv single-chain variable fragment
CRS cytokine release syndrome
IL-6R IL-6 receptor
iCAR inhibitory CAR
PRES posterior reversible encephalopathy syndrome
PCR polymerase chain reaction
BCMA B-Cell maturation antigen
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Ig immunoglobulin
ASH American Society of Hematology
VGPR very good partial response
PR partial response
PD progressive disease
SD stable disease
CR complete response
NHL Non Hodgkin’s lymphoma
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Figure 1. 
Comparative description of CAR-T cell strategies that have been used as immunotherapies 
against multiple myeloma
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